Ceribell to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

Rhea-AI Summary

Ceribell (Nasdaq: CBLL), a medical technology company specializing in neurological condition diagnosis and management, has announced its participation in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum. CFO Scott Blumberg will engage in a fireside chat on Thursday, November 21, 2024, at 10:00 a.m. PST / 1:00 p.m. EST. The event will be accessible via live and archived webcast through Ceribell's Investor Relations website section.

News Market Reaction – CBLL

-2.35%

1 alert

-2.35% News Effect

On the day this news was published, CBLL declined 2.35%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

SUNNYVALE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Scott Blumberg, CFO, will participate in a fireside chat at the upcoming Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum. The fireside chat will take place on Thursday, November 21, 2024, at 10:00 a.m. Pacific Standard Time / 1:00 p.m. Eastern Standard Time. 

Event: Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
Date: Thursday, November 21, 2024 
Time: 10:00 a.m. PST / 1:00 p.m. EST

A live and archived webcast of the fireside chat will be available in the "Investor Relations" section of the Ceribell website at https://investors.ceribell.com/. 

About CeriBell Inc.
Ceribell is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. Ceribell has developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, highly portable, and rapidly deployable hardware with sophisticated artificial intelligence (“AI”)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. The Ceribell System is FDA 510(k) cleared for indicating suspected seizure activity and currently utilized in intensive care units and emergency rooms across the U.S. Ceribell is headquartered in Sunnyvale, California. For more information, please visit www.ceribell.com or follow the company on LinkedIn.  

Investor Contact
Brian Johnston or Laine Morgan
Gilmartin Group
Investors@ceribell.com

Media Contact
Corrie Rose
Press@ceribell.com

FAQ

When is Ceribell (CBLL) participating in the Canaccord Genuity MedTech Forum 2024?

Ceribell (CBLL) will participate in the Canaccord Genuity MedTech Forum on Thursday, November 21, 2024, at 10:00 a.m. PST / 1:00 p.m. EST.

How can I watch Ceribell's (CBLL) fireside chat at the Canaccord Forum?

You can watch the fireside chat through a live or archived webcast available in the Investor Relations section of Ceribell's website at investors.ceribell.com.

What is the focus of Ceribell's (CBLL) business?

Ceribell (CBLL) is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions.

Who will represent Ceribell (CBLL) at the Canaccord Genuity Forum 2024?

Scott Blumberg, CFO of Ceribell, will represent the company and participate in a fireside chat at the forum.